Abstract:Two different mechanisms are considered to be the primary cause of aging. Cumulative DNA damage caused by reactive oxygen species (ROS), the by-products of oxidative phosphorylation, is one of these mechanisms (ROS concept). Constitutive stimulation of mitogen- and nutrient-sensing mTOR/S6 signaling is the second mechanism (TOR concept). The flow- and laser scanning- cytometric methods were developed to measure the level of the constitutive DNA damage/ROS- as well as of mTOR/S6- signaling in individual cells. Specifically, persistent activation of ATM and expression of γH2AX in untreated cells appears to report constitutive DNA damage induced by endogenous ROS. The level of phosphorylation of Ser235/236-ribosomal protein (RP), of Ser2448-mTOR and of Ser65-4EBP1, informs on constitutive signaling along the mTOR/S6 pathway. Potential gero-suppressive agents rapamycin, metformin, 2-deoxyglucose, berberine, resveratrol, vitamin D3 and aspirin, all decreased the level of constitutive DNA damage signaling as seen by the reduced expression of γH2AX in proliferating A549, TK6, WI-38 cells and in mitogenically stimulated human lymphocytes. They all also decreased the level of intracellular ROS and mitochondrial trans-membrane potential ΔΨm, the marker of mitochondrial energizing as well as reduced phosphorylation of mTOR, RP-S6 and 4EBP1. The most effective was rapamycin. Although the primary target of each on these agents may be different the data are consistent with the downstream mechanism in which the decline in mTOR/S6K signaling and translation rate is coupled with a decrease in oxidative phosphorylation, (revealed by ΔΨm) that leads to reduction of ROS and oxidative DNA damage. The decreased rate of translation induced by these agents may slow down cells hypertrophy and alleviate other features of cell aging/senescence. Reduction of oxidative DNA damage may lower predisposition to neoplastic transformation which otherwise may result from errors in repair of DNA sites coding for oncogenes or tumor suppressor genes. The data suggest that combined assessment of constitutive γH2AX expression, mitochondrial activity (ROS, ΔΨm) and mTOR signaling provides an adequate gamut of cell responses to evaluate effectiveness of gero-suppressive agents.

From rapalogs to anti-aging formula

The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging

Targeting the biology of aging with mTOR inhibitors

Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells.

Koschei the immortal and anti-aging drugs

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

Cell senescence, rapamycin and hyperfunction theory of aging

Towards natural mimetics of metformin and rapamycin

Rapalink-1 reveals novel mTOR-dependent genes and an agmatinergic axis-based metabolic feedback regulating mTOR activity and lifespan

Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks

Hormetic effect of low doses of rapamycin triggers anti-aging cascades in WRL-68 cells by modulating an mTOR-mitochondria cross-talk

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling

mTOR and Aging: An Old Fashioned Dress

Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans

Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics

The mTOR–lysosome axis at the centre of ageing

Distinct and Additive Effects of Calorie Restriction and Rapamycin in Aging Skeletal Muscle

Autophagy and Cardiovascular Aging Lesson Learned from Rapamycin

A DUAL MTOR/NAD+ ACTING GEROTHERAPY

Rapamycin's lifespan effect is modulated by mito-nuclear epistasis in Drosophila

A combination of the geroprotectors trametinib and rapamycin is more effective than either drug alone